The firm is now launching the test in Europe, supported by results from a multicenter prospective study showing high sensitivity in detecting bladder cancer.
The company will still provide interpretation-only services, but by adding in-house testing it has dramatically increased its customer base.
The deal will help the Finnish diagnostics company expand its offerings of PCR-based gastrointestinal diagnostic tests.
Devyser recently launched NGS-based tests for cystic fibrosis and the BRCA genes and aims to launch others in oncology, reproductive health, and genetic disease.
The companies intend to bring companion diagnostics through US Food and Drug Administration clearance using ArcherDX's AMP chemistry and Illumina's MiSeqDx.
The grants are strictly for new research, but Rice University scientist David Zhang is always looking for commercialization opportunities with his startup, Searna.
The partners will develop multiplex tests to detect human pathogens in 75 minutes on Grenier's PCR-based Genspeed Test System.
The firm now expects to launch the ePlex in Europe in the first quarter of 2016, after which it will pursue FDA approval.
Researchers followed individuals from more than two-dozen households for a year, tracking self-reported symptoms and respiratory virus DNA in nasal swab samples.
The contract is to further the company's work to develop methodologies aimed at Francisella tularensis, Escherichia coli, and Babesia microti.
An opinion piece in the New York Times urges lawmakers to keep genetic protections in place.
Research funding in Canada is to remain mostly the same, ScienceInsider reports.
In Science this week: random DNA replication errors play role in cancer, and more.
The Bill and Melinda Gates Foundation embarks on an open-access publishing path.